Abstract:Objective: The aim of this study was to evaluate the efficacy of a new ultrasound contrast agent, SonoVue, in diagnosis and differential diagnosis of liver lesions.Methods: Thirty-one patients with difficult differential diagnosis or highly suspected for liver lesions on CT, MRI, or conventional US were studied. A dose of 2.4 ml of SonoVue (Bracco, Italy) was infused intravenously within 30 sec. The enhancement level was monitored with a nonlinear scanning mode using an Acuson Sequoia-512 scanner with 6C-2, 4C-1 probes. The comparison examinations were performed with physical examination in all cases and with library examination in 16 patients before and after SonoVue injection. The histopathalogical diagnoses were obtained in 20 patients after SonoVue enhanced US examination. The other diagnoses were confirmed on CT, MRI, and DSA. Twenty patients had malignant liver lesions (16 hepatocellular carcinomas, 4 metastases), while 11 had benign lesions (4 hemangiomas, 2 focal nodular hyperplasias, 5 others).Results: 1) After SonoVue injection, the number of lesions without flow signal intralesions dropped from 15 to 2 with nonlinear scanning modes. 2) The positive diagnoses compared to the histopathalogical diagnoses increased after SonoVue in nonlinear scanning modes (p<0.05). 3) There was no difference in physical examination and library examinations before and after SonoVue injection.Conclusions: SonoVue is useful in visualizing tumor vessel and characterizing liver tumors. It is a safe, efficient ultrasound contrast agent and convenient for use. Objective: The aim of this study was to evaluate the efficacy of a new ultrasound contrast agent, SonoVue, in diagnosis and differential diagnosis of liver lesions. Methods: Thirty-one patients with difficult differential diagnosis or highly suspected for liver lesions on CT, MRI, or conventional US were studied. A dose of 2.4 ml of SonoVue (Bracco, Italy) was infused intravenously within 30 sec. The enhancement level was monitored with a nonlinear scanning mode using an Acuson Sequoia-512 scanner with 6C-2, 4C-1 probes. The comparison examinations were performed with physical examination in all cases and with library examination in 16 patients before and after SonoVue injection. The histopathalogical diagnoses were obtained in 20 patients after SonoVue enhanced US examination. The other diagnoses were confirmed on CT, MRI, and DSA. Twenty patients had malignant liver lesions (16 hepatocellular carcinomas, 4 metastases), while 11 had benign lesions (4 hemangiomas, 2 focal nodular hyperplasias, 5 others). Results: 1) After SonoVue injection, the number of lesions without flow signal intralesions dropped from 15 to 2 with nonlinear scanning modes. 2) The positive diagnoses compared to the histopathalogical diagnoses increased after SonoVue in nonlinear scanning modes (p<0.05). 3) There was no difference in physical examination and library examinations before and after SonoVue injection. Conclusions: SonoVue is useful in visualizing tumor vessel and characterizing liver tumors. It is a safe, efficient ultrasound contrast agent and convenient for use.

A Phase 3 Multicentre, Randomised, Comparative Study of the Efficacy and Safety of Sonazoid and SonoVue in Subjects with Focal Liver Lesions Undergoing Pre- and Post-Contrast Ultrasound Imaging

Prospective Assessment of Diagnostic Efficacy and Safety of SonazoidTM and SonoVue® Ultrasound Contrast Agents in Patients with Focal Liver Lesions

Contrast-enhanced ultrasound imaging of the liver: a review of the clinical evidence for SonoVue and Sonazoid

Comparison of Sonazoid and Sonovue in the Diagnosis of Focal Liver Lesions: A Preliminary Study.

The Clinical Use of Contrast - Enhanced Gray - Scale Ultrasonography in the Diagnosis of Focal Liver Lesions

Improved differential diagnosis of focal liver disease using SonoVue with nonlinear scanning mode

Head-to-head Comparison of Sonazoid and SonoVue in the Diagnosis of Hepatocellular Carcinoma for Patients at High Risk

Focal Liver Lesions - Can Sonovue-Enhanced Ultrasound Be Used To Differentiate Malignant From Benign Lesions?

Comparison of Sonazoid contrast-enhanced ultrasound and contrast-enhanced MRI in the diagnosis of focal liver lesions

A Comparative Study of SonoVue and Sonazoid for Contrast-Enhanced Ultrasound CT/MRI Fusion Guidance During Radiofrequency Ablation of Poorly Visualized Hepatic Malignancies: A Prospective Intra-Individual Analysis

Characterization Of Small Focal Liver Lesions Using Real-Time Contrast-Enhanced Sonography - Diagnostic Performance Analysis In 200 Patients

Compared with SonoVue ® LR-5, Sonazoid ® modified LR-5 has better diagnostic sensitivity for hepatocellular carcinoma: a systematic review and meta-analysis

Comparison of SonoVue and Sonazoid in Localization of Sentinel Lymph Nodes in Early Breast Cancer Patients

Characterization of Small Focal Liver Lesions Using Real‐time Contrast‐Enhanced Sonography

Comparison Between SonoVue and Sonazoid Contrast‐Enhanced Ultrasound in Characterization of Focal Nodular Hyperplasia Smaller Than 3 Cm

Contrast-Enhanced Ultrasound With SonoVue and Sonazoid for the Diagnosis of Colorectal Liver Metastasis After Chemotherapy.

Value of Sonazoid-enhanced ultrasonography in characterizing indeterminate focal liver lesions on gadoxetic acid-enhanced liver MRI in patients without risk factors for hepatocellular carcinoma

0605: Treatment Response Evaluation with 3D Contrast-Enhanced Ultrasound for Liver Cancer after Local Therapies

Assessment of Arterial-Phase Hyperenhancement and Late-Phase Washout of Hepatocellular Carcinoma—a Meta-Analysis of Contrast-Enhanced Ultrasound (CEUS) with SonoVue® and Sonazoid®

Clinical Value of Contrast-Enhanced Ultrasonography in the Characterization of Focal Liver Lesions: a Prospective Multicenter Trial.

A Review of Contrast-enhanced Ultrasound using SonoVue® and Sonazoid TM in Non-hepatic Organs